Brokerages expect that OrthoPediatrics Corp. (NASDAQ:KIDS) will announce earnings of ($0.38) per share for the current quarter, Zacks reports. Three analysts have made estimates for OrthoPediatrics’ earnings, with estimates ranging from ($0.27) to ($0.24). OrthoPediatrics posted earnings of ($0.29) per share during the same quarter last year, which indicates a negative year over year growth rate of 31%. The firm is expected to issue its next quarterly earnings results on Wednesday, March 3rd.
On average, analysts expect that OrthoPediatrics will report full year earnings of ($1.33) per share for the current financial year, with EPS estimates ranging from ($1.35) to ($1.30). For the next year, analysts forecast that the firm will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.87) to ($0.37). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for OrthoPediatrics.
OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Wednesday, November 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.07. The company had revenue of $22.21 million for the quarter, compared to analyst estimates of $19.73 million. OrthoPediatrics had a negative net margin of 34.26% and a negative return on equity of 11.57%.
In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 8,000 shares of OrthoPediatrics stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $47.04, for a total value of $376,320.00. Following the completion of the transaction, the general counsel now owns 31,637 shares of the company’s stock, valued at $1,488,204.48. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Stephen F. Burns sold 7,000 shares of the business’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $49.29, for a total transaction of $345,030.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,750 shares of company stock valued at $894,563. 33.60% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio acquired a new position in shares of OrthoPediatrics during the third quarter valued at $123,000. California State Teachers Retirement System boosted its holdings in shares of OrthoPediatrics by 10.1% during the third quarter. California State Teachers Retirement System now owns 19,843 shares of the company’s stock valued at $911,000 after acquiring an additional 1,825 shares during the period. AQR Capital Management LLC acquired a new position in shares of OrthoPediatrics during the third quarter valued at $298,000. Summit Partners Public Asset Management LLC boosted its holdings in shares of OrthoPediatrics by 15.8% during the third quarter. Summit Partners Public Asset Management LLC now owns 541,169 shares of the company’s stock valued at $24,850,000 after acquiring an additional 73,831 shares during the period. Finally, First Light Asset Management LLC boosted its holdings in shares of OrthoPediatrics by 85.5% during the third quarter. First Light Asset Management LLC now owns 224,042 shares of the company’s stock valued at $10,288,000 after acquiring an additional 103,269 shares during the period. 66.86% of the stock is owned by institutional investors.
KIDS opened at $41.25 on Tuesday. The firm has a market capitalization of $806.64 million, a P/E ratio of -28.65 and a beta of 0.70. The firm’s 50 day moving average is $45.50 and its 200-day moving average is $46.01. OrthoPediatrics has a 52-week low of $32.21 and a 52-week high of $55.98.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Featured Story: How to identify percentage decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.